filmov
tv
Interpreting Lung Cancer Biomarker Testing Results
Показать описание
Support for this educational program provided by Amgen, AstraZeneca, Blueprint Medicines, Bristol Myers Squibb, Genentech, Lilly Oncology, Merck, Novartis and Pfizer.
American Lung Association
next-generation
sequencing
ngs
liquid biopsy
pdl1
Рекомендации по теме
0:01:24
Interpreting Lung Cancer Biomarker Testing Results
0:02:20
The interpretation of cancer biomarker test results
0:02:16
How to Test for Lung Cancer Biomarkers
0:03:33
What is ‘comprehensive biomarker testing’ and why is it important in lung cancer?
0:56:16
Biomarker Testing for Lung Cancer Webinar
0:05:50
How is biomarker testing carried out?
0:48:19
Lung Cancer Biomarker Testing
0:57:40
John Longshore - Recent Progress in Predictive Biomarker Testing in Oncology
0:29:11
Why Comprehensive Genomic Profiling (CGP) is Important in Advanced NSCLC
0:56:17
Reducing time for clinical NGS test interpretation by 85%
0:05:31
Biomarkers in NSCLC - Targeted Therapies in Lung Cancer 2023
0:27:49
Lung cancer: Pre-analytical phase challenges and biomarker testing
0:02:04
Lung cancer screening via biomarkers
0:04:02
Current and Future Biomarker Testing in Lung Cancer
0:08:09
How Does Data Inform Lung Cancer Biomarker Testing?
0:05:21
How Are Barriers in Lung Cancer Biomarker Testing Being Addressed?
0:58:09
What is Biomarker Testing for Advanced Lung Cancer and Why Is It Important?
0:01:39
When should a lung cancer patient be retested for biomarkers?
1:39:03
Everything You Need to Know About Biomarker Testing and Treatment of Genomically Altered NSCLC
0:02:28
Which biomarkers exist for Non-Small Cell Lung Cancer (NSCLC)?
0:49:54
Practical Principles of Biomarker Testing in Advanced Non-Small Cell Lung Cancer
1:00:20
Surgeons and Comprehensive Biomarker Testing for Lung Cancer Patients, November 4, 2021
0:00:31
Lung Cancer Biomarker Testing: A Caregiver’s Perspective
1:01:57
Lung Cancer Biomarker Testing: Improving Turnaround from Presentation to Treatment